Evidence map›Paper›PMID 39738894›Full record

ArticleJournal of cancer research and clinical oncology2024

Case study of a neuroendocrine tumor of uncertain origin: single-cell transcriptomics unravels potential primary location.

Frolova Tatyana, Ekaterina Avsievich, Diana Salimgereeva, Zoia Antysheva, Alesia Maluchenko, Denis Maksimov, Ilia Feidorov, Mark Voloshin, Olga Glazova, Natalia Bodunova and 3 more

Abstract readCase Reports
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Frolova TatyanaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, 125315, Russia.
Ekaterina AvsievichMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Diana SalimgereevaMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Zoia AntyshevaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, 125315, Russia.
Alesia MaluchenkoMoscow Center for Advanced Studies, Kulakova str. 20, Moscow, 123592, Russia.
Denis MaksimovFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, 125315, Russia.
Ilia FeidorovMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Mark VoloshinMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Olga GlazovaMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Natalia BodunovaMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Nikolay KarnaukhovMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Pavel VolchkovMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Julia KrupinovaMoscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia. y.krupinova@mknc.ru.ORCID https://orcid.org/0000-0001-7963-5022

Funding

Moscow government 1702-13/23the Ministry of Science and Higher Education of the Russian Federation 075-03-2022-107/10
6 · The paper itself

Abstract

purposeDetermining the primary origin of non-organ-confined neuroendocrine tumors (NETs) for accurate diagnosis and management. Neuroendocrine tumors are rare neoplasms with diverse clinical behaviors. Determining their primary origin remains challenging in cases of non-organ-confined NETs. This study explores the histogenesis of a retroperitoneal, non-functional NET localized between the duodenum and pancreatic head, utilizing advanced molecular diagnostics to elucidate its probable primary source.

methodsInitial diagnostic methods, including imaging and histopathology, failed to resolve the tumor's origin. The tumor was subjected to single-cell RNA sequencing (scRNA-seq) and whole exome sequencing (WES). Publicly available transcriptomic datasets from pancreatic and small intestine NETs were used to develop and validate a molecular gene signature for tissue-of-origin identification.

resultsThe gene signature distinguished pancreatic and small intestine NETs with high accuracy. The tumor cells presented a molecular profile consistent with a pancreatic origin, likely derived from ectopic pancreatic tissue.

conclusionsThis case demonstrates the value of integrating scRNA-seq and WES for the molecular characterization of complex NETs. Identifying the tumor's pancreatic origin informed a targeted management approach, avoiding unnecessary systemic treatment and underscoring the potential of single-cell approaches in personalized oncology.

Indexed as

Neuroendocrine TumorsSingle-Cell AnalysisTranscriptomeExome SequencingGene Expression ProfilingHumansPancreatic NeoplasmsDuodenal NETEctopic pancreatic tissueNeuroendocrine tumorNon-organ-confined NETPancreatic NETSingle-cell RNA‐seq

Identifiers

PMID39738894
PMCPMC11688255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.